Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
WeybridgeSurreyKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
24,524
Stocks News & Analysis
stocks
ASX energy share undervalued ahead of earnings
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
stocks
This onetime AI market darling is now surprisingly undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.40 | 69.70 | 0.77% |
| CAC 40 | 8,634.03 | 124.39 | 1.46% |
| DAX 40 | 26,077.62 | 448.38 | 1.75% |
| Dow JONES (US) | 53,076.02 | 590.99 | 1.13% |
| FTSE 100 | 10,846.16 | 21.89 | -0.20% |
| HKSE | 26,009.40 | 124.97 | 0.48% |
| NASDAQ | 25,775.21 | 401.36 | 1.58% |
| Nikkei 225 | 63,754.90 | 607.12 | -0.94% |
| NZX 50 Index | 13,774.93 | 75.65 | 0.55% |
| S&P 500 | 7,572.43 | 82.71 | 1.10% |
| S&P/ASX 200 | 9,019.30 | 70.30 | 0.79% |
| SSE Composite Index | 3,809.66 | 22.60 | -0.59% |